Evidence map›Paper›PMID 26355082›Full record

ArticleJournal of virology2015

Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.

Young-Chan Kwon, Sandip K Bose, Robert Steele, Keith Meyer, Adrian M Di Bisceglie, Ratna B Ray, Ranjit Ray

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. The Role of Endoglin in Hepatocellular Carcinoma.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Young-Chan KwonDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.
Sandip K BoseDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA Department of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, Missouri, USA.
Robert SteeleDepartment of Pathology, Saint Louis University, St. Louis, Missouri, USA.
Keith MeyerDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.
Adrian M Di BisceglieDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA Department of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, Missouri, USA.
Ratna B RayDepartment of Pathology, Saint Louis University, St. Louis, Missouri, USA.
Ranjit RayDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA Department of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, Missouri, USA rayr@slu.edu.
Saint Louis University · US

Funding

Innate Immunity and Hepatitis C Virus InfectionR01DK081817 · NIDDK · SAINT LOUIS UNIVERSITY · PI RAY, RATNA B. · 2009 to 2020
$3.3M
Mechanisms of Liver Disease Progression by Hepatitis C VirusR01DK080812 · NIDDK · SAINT LOUIS UNIVERSITY · PI RAY, RANJIT · 2009 to 2013
$1.6M
NIDDK NIH HHS DK080812NIDDK NIH HHS DK081817NIDDK NIH HHS R01 DK080812NIDDK NIH HHS R01 DK081817
6 · The paper itself

Abstract

unlabelledWe have previously reported that hepatitis C virus (HCV) infection of primary human hepatocytes (PHH) induces the epithelial mesenchymal transition (EMT) state and extends hepatocyte life span (S. K. Bose, K. Meyer, A. M. Di Bisceglie, R. B. Ray, and R. Ray, J Virol 86:13621-13628, 2012, http://dx.doi.org/10.1128/JVI.02016-12). These hepatocytes displayed sphere formation on ultralow binding plates and survived for more than 12 weeks. The sphere-forming hepatocytes expressed a number of cancer stem-like cell (CSC) markers, including high levels of the stem cell factor receptor c-Kit. The c-Kit receptor is regarded as one of the CSC markers in hepatocellular carcinoma (HCC). Analysis of c-Kit mRNA displayed a significant increase in the liver biopsy specimens of chronically HCV-infected patients. We also found c-Kit is highly expressed in transformed human hepatocytes (THH) infected in vitro with cell culture-grown HCV genotype 2a. Further studies suggested that HCV core protein significantly upregulates c-Kit expression at the transcriptional level. HCV infection of THH led to a significant increase in the number of spheres displayed on ultralow binding plates and in enhanced EMT and CSC markers and tumor growth in immunodeficient mice. The use of imatinib or dasatinib as a c-Kit inhibitor reduced the level of sphere-forming cells in culture. The sphere-forming cells were sensitive to treatment with sorafenib, a multikinase inhibitor, that is used for HCC treatment. Further, stattic, an inhibitor of the Stat3 molecule, induced sphere-forming cell death. A combination of sorafenib and stattic had a significantly stronger effect, leading to cell death. These results suggested that HCV infection potentiates CSC generation, and selected drugs can be targeted to efficiently inhibit cell growth. IMPORTANCE: HCV infection may develop into HCC as an end-stage liver disease. We focused on understanding the mechanism for the risk of HCC from chronic HCV infection and identified targets for treatment. HCV-infected primary and transformed human hepatocytes (PHH or THH) generated CSC. HCV-induced spheres were highly sensitive to cell death from sorafenib and stattic treatment. Thus, our study is highly significant for HCV-associated HCC, with the potential for developing a target-specific strategy for improved therapies.

Indexed as

AnimalsBiomarkers, TumorCarcinoma, HepatocellularCyclic S-OxidesDasatinibEpithelial-Mesenchymal TransitionFemaleHepacivirusHepatitis CHepatocytesHumansImatinib MesylateLiver NeoplasmsMiceNeoplasm TransplantationNeoplastic Stem CellsBiomarkers, TumorCyclic S-OxidesDasatinibImatinib MesylateNiacinamidePhenylurea CompoundsProto-Oncogene Proteins c-kitRNA, MessengerSorafenibSTAT3 protein, humanSTAT3 Transcription Factorstattic

Identifiers

PMID26355082
PMCPMC4645669
OpenAlexW2120054052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.